Drug major Sun Pharma on Saturday said it is discontinuing operations at two clinical pharmacology units in Vadodara (Gujarat) to bring in efficiencies in cost and processes. "While we continue to make investments in our R&D operations, we also constantly evaluate our resources and future capacity requirements to bring in efficiencies in cost and processes," a Sun Pharmaceutical Industries spokesperson said in a statement. To ensure optimal utilisation of clinical pharmacology units (CPUs) that conduct bio-equivalence studies, the company is discontinuing operations at two centers at Tandalja and Akota in Vadodara, the spokesperson added. "The bio-equivalence studies from these centers will be transferred to our other facilities. We are offering full support to the affected employees and helping them with out placement services," the spokesperson said. As per industry sources, the move would impact around 80 staffers at the two locations. Sun Pharma has six major R&D centers ..
from Companies https://ift.tt/2OAOxtn
via IFTTT
Subscribe to:
Post Comments (Atom)
Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO
However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...
-
It is looking at raising a debt of Rs 450 crore for the Eluru project and Rs 400 crore for the Bengaluru project, the official added from ...
-
With 73,642 new daily recoveries, the most so far, India's recovery rate has improved to 77.32%, while death rate has come down to 1.72%...
-
Modi said political stability through a massive mandate for his government alongside predictable policy provides a unique opportunity for In...
No comments:
Post a Comment